👉LIMN is TODAY’S #1 ALERT 👈

The Cancer Treatment Breakthrough That Could Rewrite the Rules of Immunotherapy

It started with a mystery.

Why do some of the world’s most advanced cancer drugs… simply stop working?

Doctors had seen it happen countless times. Patients with hope in their eyes start treatment, tumors shrink, the charts look better… and then, without warning, the cancer fights back.

The drugs didn’t fail because they were bad. They failed because cancer had a secret trick…

A biological cloaking device that told the immune system: “Don’t attack me.” 

For years, researchers tried to crack that code. Billions of dollars went into a class of drugs called immune checkpoint inhibitors — medicines that “unlock” the immune system so it can recognize and kill cancer cells.

Some worked wonders. But the success rate was still frustratingly low, especially for aggressive cancers.

Then came a new idea.

What if you could take today’s best immune therapies… and supercharge them by blocking that “Don’t Eat Me” signal?

What if you could make the immune system’s attack dogs — the macrophages — recognize and destroy tumors the moment they see them?

One small U.S. biotech has spent years perfecting this approach. It claims to have solved the biggest safety problem that sank earlier attempts: The side effects that came when these drugs attacked healthy blood cells.

And now, with a safer, more targeted version in hand… they’re preparing to take it into human trials.

👉 The company’s name? Liminatus Pharma (LIMN).

Why This Approach Is Attracting Billion-Dollar Deals

Big pharma isn’t blind to the potential of this “Don’t Eat Me” signal breakthrough.

When a company shows even early success in safely targeting it, the deals can be massive:

•     AbbVie (NYSE: ABBV) — In 2020, AbbVie signed an exclusive licensing deal with I‑Mab for a CD47 antibody. The structure: $200 million upfront plus potential milestones totaling up to $1.74 billion.
•     Trillium Therapeutics — Acquired by Pfizer for $2.26 billion after showing promising early results in this same pathway.
•     I-Mab Biopharma (NASDAQ: IMAB) — Still in trials, yet commands a $350 million market valuation thanks to its own CD47 program.

These aren’t one-off flukes. They show a pattern:

When a new therapy can improve the performance of existing cancer treatments — especially blockbuster immune checkpoint inhibitors — the biggest names in the industry will pay, and they’ll pay big. 

That’s what makes LIMN so intriguing right now. 

The company believes its next-generation CD47 therapy can do what others couldn’t — deliver the cancer-killing benefits without the dangerous side effects that derailed earlier competitors.

If it’s right, this isn’t just another biotech story: It’s a chance to be positioned before a technology shift that could lead to licensing deals, acquisitions, or partnerships worth billions.

Why This Could Potentially Be One of the Fastest-Running Biotech Stocks on Nasdaq

In biotech, news can change everything overnight.

On June 9, LIMN traded at $26.68.

Today, it’s a fraction of that. 

With approximately 12.46 million shares in the public float, it doesn’t take much volume for the price to move — and move quickly.

Add to that the fact that the company has just revealed an unusual, headline-grabbing plan: a strategic review to create a separate $500 million digital asset investment vehicle.  

It’s the perfect recipe for market-moving headlines.

This new arm would operate independently of the cancer drug pipeline, aiming to raise capital through private placements, convertible instruments, and equity lines, potentially giving the company access to hundreds of millions in non-dilutive funding, while keeping its core biotech work fully funded.

If executed, it would be one of the boldest treasury strategies ever attempted by a Nasdaq-listed biotech, and it could attract entirely new classes of investors. 

When you combine the pipeline potential, M&A precedent, and capital innovation, you get a setup that’s rare on Wall Street.

Here’s why some investors are circling this story right now:

8 Reasons This Tiny Nasdaq Biotech Could Be One Breakthrough — or One Headline — Away From a Big Move

1. Next-Gen CD47 Cancer Drug — Designed to supercharge today’s best immune therapies while avoiding the blood-cell safety issues that sank earlier attempts.
2. Billion-Dollar Precedent — Similar assets have sold or been licensed for $1–$4.9 billion to major pharma players like Pfizer and AbbVie.
3. Low Float — With only 12.46M shares outstanding, LIMN’s float means the stock can run quickly on news.
4. Fast-Run Potential Proven — The stock was $26.68 as recently as June 9, proving it can move sharply when momentum hits.
5. Pipeline Beyond One Drug — Includes additional immune-oncology programs and an artificial blood joint venture for emergency and military use.
6. Bold Capital Strategy — July 25 announcement of a potential $500M digital asset investment vehicle to fund operations without heavy dilution.
7. Near-Term Catalysts — Human trials for the CD47 therapy are on the horizon, with partnership potential built into the model.
8. M&A and Partnership Appeal — If the technology delivers in trials, LIMN could become a prime acquisition target for big pharma looking to enhance their immunotherapy portfolios.

How This “Don’t Eat Me” Switch Works And Why This Company Thinks It Can Do It Safer

Think of your immune system like a neighborhood watch.

Its job is to look for anything suspicious — in this case, cancer cells — and call in the “cleanup crew” to take it out.

Some of the immune system’s most powerful cleanup tools are called macrophages. They’re like the garbage trucks of your body, finding and “eating” dangerous cells.

But cancer has learned a trick.

It puts up a “Don’t Eat Me” sign on its surface that scientists call CD47. When macrophages see the CD47 signal, they pass right by, leaving the cancer alone to grow and spread.

Now here’s where it gets exciting:

If you can block that CD47 signal, you take away the cancer’s disguise. Suddenly, the macrophages know exactly what to do by surrounding the tumor and destroying it.

The problem?

Earlier drugs that tried this caused serious side effects. That’s because CD47 isn’t just on cancer cells; it’s also on healthy red blood cells and platelets.

Blocking it everywhere sometimes caused dangerous drops in blood counts, and several big programs were shut down.

LIMN scientists think they’ve solved it.

Their CD47 drug is designed to target tumor and immune cells only, while barely touching red blood cells or platelets. In preclinical safety studies, they saw no major blood-related side effects — a key difference that could make all the difference in winning FDA approval.

If they’re right, this isn’t just about beating one type of cancer, it’s about making today’s leading cancer drugs work better, faster, and for more people.

The Size of the Prize: Two Multi-Billion-Dollar Markets

In biotech investing, size matters.

The bigger the market, the greater the upside if a company can capture even a small slice of it.

That’s why what LIMN is targeting is so remarkable — it’s not one giant market… it’s two. 

The first is one of the hottest areas in all of medicine: immuno-oncology, where the immune system is trained to hunt and destroy cancer.

The second is a sector that’s been on military wish lists and hospital procurement plans for decades: artificial blood, a technology that could save lives anywhere from a battlefield to an ambulance.

Both markets are projected to explode in value over the coming years. And with its next-generation CD47 cancer therapy and its artificial blood joint venture, LIMN has a shot at competing in both.

1. Immuno-Oncology / CD47 Therapies 

Source: Biomed Central 

Cancer drugs that enlist the immune system have changed the treatment landscape — and the revenues of the companies behind them. The two best-known PD-1 inhibitors bring in tens of billions annually (see here and here).

But scientists now believe that combining PD-1 drugs with CD47 blockers could make treatments even more effective.  

That’s where LIMN comes in with its lead candidate, IBA101 — a potentially safer, second-generation CD47 therapy designed to avoid the safety pitfalls that derailed earlier competitors. 

•     The immuno-oncology space is booming. Market analysts expect immuno-oncology drugs to grow from $32.3 billion in 2025 to $106.7 billion by 2032, at an 18.6% annual clip. A trend that strongly supports the blockbuster potential of CD47-targeted treatments.
•     The CD47 targeting therapeutics market is expected to grow at a 22.89% compound annual growth rate (CAGR) to reach approximately $18.96 billion by 2034.
•     Big pharma has already moved in: Pfizer paid $2.26 billion to acquire Trillium Therapeutics in 2021 for its CD47 program, and AbbVie signed a $2 billionlicensing deal with I-Mab in 2020 for its own CD47 antibody.

This is the same playing field LIMN is stepping onto — a space where billion-dollar buyouts have already proven the commercial potential.

2. Artificial Blood / Oxygen Carriers 

Now imagine a world where hospitals never run short of blood…

Where medics can stabilize trauma patients in minutes without worrying about blood type matching, refrigeration, or supply shortages.

That’s the promise of artificial blood. 

For decades, researchers have been chasing a viable, safe alternative to donor blood. The potential buyers aren’t just hospitals, they’re militaries, emergency services, space agencies, and even disaster relief organizations.

LIMN, through its artificial-blood joint venture, is positioning itself in the center of this future. With backing from the South Korean Ministry of National Defense and advanced R&D partners, the company is moving toward solutions that could change how the world thinks about transfusions.

•     The artificial blood market is projected to grow from $3.89 billion in 2019 to $15.4 billion by 2027, a compound annual growth rate of 18.5%.
•     The global human blood products market — the broader category that includes blood transfusions and related therapies — is valued at $38 billion in 2025, and is expected to grow to approximately USD 54 billion by 2031. 

Why This Matters for Investors

Biotechs that can move the needle in just one of these markets can transform overnight.

LIMN is aiming at both, giving it two shots on goal in industries where even a fraction of the market translates to billions in potential revenue.

Upcoming Catalysts That Could Light the Fuse

Some biotech stocks drift for years.

LIMN is not one of them.

Liminatus is sitting on multiple “binary events” — moments where a single press release can change the story overnight.

With approximately 12.46 million shares in the public float, it doesn’t take much buying pressure to send the price moving quickly. We’ve already seen what’s possible.

On June 9, this stock traded at $26.68. In the right conditions, it can run hard and fast.

Now, with regulatory filings, trial launches, and potential partnerships all lined up, the next wave of headlines could put this ticker back on the market’s radar in a big way.

Here’s what’s coming…

Key Catalysts on the Horizon

1. IND Submission for IBA101 (Late 2026): LIMN is preparing for a major leap into human studies. The company has completed all necessary safety and efficacy testing in non-human primates, conducted under GLP standards at Charles River Laboratories to support the regulatory filings. 

As a result, they plan to submit Investigational New Drug (IND) applications to both the U.S. FDA and Korea’s Ministry of Food and Drug Safety (MFDS) in the second half of 2026. 

This regulatory green light would open the door to initiating human trials and setting the stage for potentially transformative results.

2. Phase I First-in-Human Trials (Early 2027): LIMN is rapidly moving from the lab to the clinic. According to its June 2025 disclosures, the company completed all necessary preclinical testing and is now preparing for human trials.

The company has finished GLP toxicology and pharmacology studies in primates, paving the way for regulatory submissions and clinical planning. Site activations and patient screening are expected to begin in early 2027.

Liminatus is collaborating with Professor Se-Hoon Lee at Samsung Medical Center in Seoul. Planning a 3+3 dose-escalation Phase I protocol, with expansion cohorts and combination arms alongside PD-1/PD-L1 therapies to assess safety, dosing, and potential synergy.

3. Potential Big Pharma Collaborations: The trial design allows for testing alongside existing PD-1 therapies, opening the door to co-development or licensing deals if synergy is seen.
4. $500 Million Capital Strategy Decision: The Board is reviewing the creation of a separate digital asset investment arm. If approved, it could give LIMN a massive funding pool without heavy share dilution — rare in biotech.
5. Exploratory Programs in Inflammation: Early research suggests the CD47 platform could help clear harmful senescent cells in chronic inflammation, adding entirely new markets to the pipeline.
6. Market Reaction to Any Positive Data: Low float, high sensitivity to news, and a history of fast moves mean that even a small positive update could send shares ofLIMN sharply higher.
7. FDA Regulatory Visibility: LIMN is already on MarketBeat’s FDA Events Dashboard, keeping it on the radar of traders and funds who track upcoming drug milestones.

Meet the Team Steering the Breakthroughs

Behind every biotech breakthrough, there’s a team made of brains, experience — and serious hustle. LIMN has assembled just that:

Chris Kim, J.D., L.L.M. — CEO, Treasurer & Secretary. A seasoned biotech and IP attorney, Chris has guided programs through legal, regulatory, and strategic hurdles. Before leading Liminatus, he served as IP counsel to pharma giants like Merck, Pfizer, GSK, Novartis, and Bayer. 

Scott Dam — Chief Financial Officer. Enlisted during the SPAC merger in April 2025, Scott brings financial leadership crucial for navigating public markets and strategic fundraising. 

Byong C. Yoo — Chief Science Officer. Also part of the leadership team revealed after the SPAC merger completion, Dr. Yoo leads the science strategy and steers the development of Liminatus’s next-gen CD47 therapy.

Adding Depth: The Board of Directors

Liminatus recently expanded its board to include experts capable of scaling science into solutions:

Philip Lemons, a clinical R&D leader with two decades of experience working globally with institutions like Duke Clinical Research Institute. He’ll help navigate trial design and strategic alliances. 

Richard Baek, a finance and compliance specialist who ensures the company stays audit-ready and accountable, a must for any emerging public company. 

Why This Team Inspires Confidence

1. Scientific Strength + Legal Savvy: With Dr. Yoo and Chris Kim leading the scientific and IP fronts, the pipeline isn’t just smart — it’s protected.
2. Financial Competence: Scott Dam and Richard Baek cover the numbers with their fundraising savvy and compliance so investors don’t have to worry.
3. Operational & Clinical Credibility: Adding Lemons bridges the lab and the clinic. Exactly what LIMN needs as it moves into human trials.

In plain terms: this is a lean team with heavyweight experience that is built to move fast, navigate bureaucracy, and deliver results.

Low Float. Big Markets. Binary Events Ahead.
The Clock Is Ticking.

In biotech, timing is everything, and right now, LIMN is sitting on a perfect storm of opportunity.   

A low 12.46 million share float, two billion-dollar market targets, and multiple binary events that could hit the tape over the next 12–18 months.

We’ve already seen what this stock can do when it catches momentum…

On June 9, shares hit $26.68. With the right news, it probably won’t take much for a potential move like that to happen again.

Between its potentially safer CD47 therapy, its military-backed artificial blood program, and a board exploring a $500 million capital strategy, LIMN is positioned for news flow that could wake up the market in a big way.

Biotech investors have learned the hard way that waiting for the press release is often too late. The market tends to price in good news fast, sometimes in a single trading session.

That’s why if you’re watching LIMN, you’ll want to be ready before the headlines hit. 

👉  LIMN is TODAY’S #1 ALERT 👈

The next phase of this story could move quickly and the setup is already in place. 

And of course, always approach your trading in a responsible manner,  remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

To Your Success,

Jeff Bishop

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Legends Media for advertising Liminatus Pharma, Inc for a one day marketing program starting on August 14, 2025. It might seem obvious, but while our client claims not to own any shares in Liminatus Pharma, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Liminatus Pharma, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.